Publication date: Mar 16, 2019
At a minimum follow-up of 12 months, incidence of treatment-related grade 3 to 5 AEs was 34% with NIVO3+IPI1 versus 48% with NIVO1+IPI3 (P=. 006).
In descriptive analyses, objective response rate was 45. 6% in the NIVO3+IPI1 group and 50. 6% in the NIVO1+IPI3 group, with complete responses in 15. 0% and 13. 5% of patients, respectively.
The CheckMate 511 study met its primary end point, demonstrating a significantly lower incidence of treatment-related grade 3-5 AEs with NIVO3+IPI1 versus NIVO1+IPI3.
- Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial.
- Treatment patterns and outcomes for patients with unresectable stage III and metastatic melanoma in the USA.
- Comparative efficacy of combination immunotherapy and targeted therapy in the treatment of BRAF-mutant advanced melanoma: a matching-adjusted indirect comparison.